Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
about
The epigenetic landscape of acute myeloid leukemiaThe role of FLT3 in haematopoietic malignanciesStructural and functional alterations of FLT3 in acute myeloid leukemiaDownstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implicationsCross-platform analysis of cancer microarray data improves gene expression based classification of phenotypesMolecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyClass III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory AnalysisThe Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia TherapyOxidative stress responses and NRF2 in human leukaemiaMolecular prognostic factors in cytogenetically normal acute myeloid leukemiaGenomics of acute myeloid leukemiaAn overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentFLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemiaPhase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemiaClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewSurvey of activated FLT3 signaling in leukemiaThe FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsMll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemiasPrognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies.Significance of oncogenes and tumor suppressor genes in AML prognosis.SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth.Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AMLA pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes.FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical SignificanceSalvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDLong FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.The Cytokine Flt3-Ligand in Normal and Malignant HematopoiesisFLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemiaOncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virusThe AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemiaEffect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.
P2860
Q21284742-9311AE54-E340-460A-8528-26F0168ED525Q24319174-99781503-6451-4E18-90EC-30FEB05A6889Q24338964-48ACFA73-1124-40E5-9634-ABB4982CC685Q24617091-0042B375-1B04-4C23-A1C3-DFBE5D1B200EQ24811346-4CEDE9AD-23E4-449E-AC46-1349CD5F2795Q26749870-AED0372B-A627-4F6A-A391-E8AE2D99060EQ26797245-D26EE575-9217-4EC7-A28B-F62121CBE911Q26799596-D774DAF8-6776-4852-9B35-A3B5B0EE18FDQ26864239-0CAF6649-A13B-4CD3-9321-497C2B9D90F7Q26998811-A3FAA716-E4AE-4041-8543-CC0626542235Q27021548-AA66D615-17CD-4C33-9C0A-A95DE27C4CFFQ27027207-548BBD05-D425-493E-AA61-E16D974BA982Q27028163-26516C5F-CC12-4D54-B529-2DF8139955DDQ27851415-A6901125-39B6-4AB6-A435-4677C22E2487Q27851642-D3FEB240-888F-4772-826C-1EC9D9365ACBQ27851909-EA4DEEB5-EACB-45DB-AA72-70F6A6BADE0BQ27852046-5FFEF895-AE26-45FE-83ED-20B0FA40D44EQ28186429-110EDEB1-8BD1-43B3-8755-DEFD154B8011Q28271726-618D94AB-4FB2-44CD-A65B-DBEB6B9BA048Q28301344-C0E9F703-9101-47B7-A762-497C25DE04B7Q28477934-A06A5E58-7515-46B9-ABB2-5C13533A7525Q28535342-80A4D768-0F88-49B3-8F91-B3DE8946C96CQ28594733-D93C1EFF-8A5E-4A47-A85A-46AE15F394E1Q30248904-6009CCB2-F158-4187-B3F3-EAC8E0D4BA8CQ30250315-75675CDD-AE08-43C2-BA7C-A4520EAB2A66Q30420638-B0AB0970-8F96-43B8-9C63-DF3098617D44Q33216322-F0C8F58B-C96B-47EA-B161-CA7741C46880Q33392185-55154E3A-F6CA-4C43-BF36-29655E650AF0Q33702150-D77361FD-1DC2-49F1-A39D-A9684306F377Q33716570-1F863E3E-BB40-4EF7-B2D0-5934DA09311AQ33778374-CF9623D8-8CE8-4649-8745-EF8494E2E6C0Q33798909-66E73707-F967-4AD1-A201-98EF8C19443EQ33829079-9D3A0F70-9A7B-42E6-97D7-BD6943C169AFQ33829117-37EB3D7E-BA62-45B1-866D-86CD2BD2C636Q33838356-C8ABF7B6-0902-4619-B82E-F513E968EAC2Q33856839-8DF77293-3811-4EC8-A26B-C9E9F214738AQ33895494-1490D250-05F8-4D5C-A1CE-0D49F33DC328Q33895709-D39F33D4-90D7-4437-9E8E-697BC1785B6AQ33913329-90401852-BF81-4D95-B7DD-7BBEE13EDB00Q33968372-4B7385B2-7291-4961-8F71-D1DA53F276A0
P2860
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Analysis of FLT3 length mutati ...... n of minimal residual disease.
@ast
Analysis of FLT3 length mutati ...... n of minimal residual disease.
@en
Analysis of FLT3 length mutati ...... n of minimal residual disease.
@nl
type
label
Analysis of FLT3 length mutati ...... n of minimal residual disease.
@ast
Analysis of FLT3 length mutati ...... n of minimal residual disease.
@en
Analysis of FLT3 length mutati ...... n of minimal residual disease.
@nl
prefLabel
Analysis of FLT3 length mutati ...... n of minimal residual disease.
@ast
Analysis of FLT3 length mutati ...... n of minimal residual disease.
@en
Analysis of FLT3 length mutati ...... n of minimal residual disease.
@nl
P2093
P50
P356
P1433
P1476
Analysis of FLT3 length mutati ...... n of minimal residual disease.
@en
P2093
Christian Wuchter
Cristina Maria Sauerland
Helmut Löffler
Hubert Serve
Martin Dugas
Peter Staib
Thomas Büchner
Wolfgang Hiddemann
Wolfgang Kern
P356
10.1182/BLOOD.V100.1.59
P407
P577
2002-07-01T00:00:00Z